Expression of wild-type p53 gene confers increased sensitivity to radiation and chemotherapeutic agents in human esophageal carcinoma cells

International Journal of Oncology

Volumn 14, Issue 6, 1999, Pages 1081-1085

  Matsubara, Hisahiro ^a   Kimura, Masaki ^a,b   Sugaya, Makoto ^a   Koide, Yoshio ^a   Gunji, Yoshio ^a   Takegana, Keizo ^c   Asano, Takehide ^a   Ochiai, Takenori ^a   Isono, Kaichi ^a   Sakiyama, Shigeru ^d   Tagawa, Masatoshi ^b  

^a CHIBA UNIVERSITY   (Japan)

^b Division of Pathology   (Japan)

^c Division of Chemotherapy   (Japan)

^d CHIBA CANCER CENTER   (Japan)

Author keywords

Chemosensitivity; Esophageal cancer; Gene therapy; p53; Radiosensitivity

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; PROTEIN P53;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CARCINOMA; CELL DIVISION; DRUG EFFECT; ESOPHAGUS TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; GENETICS; HUMAN; MICROBIOLOGICAL EXAMINATION; MOUSE; MUTATION; NUDE MOUSE; PHYSIOLOGY; RADIATION DOSE; RETROVIRUS; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; CELL DIVISION; CISPLATIN; ESOPHAGEAL NEOPLASMS; ETOPOSIDE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROBIAL SENSITIVITY TESTS; MUTATION; NEOPLASM TRANSPLANTATION; RADIATION TOLERANCE; RETROVIRIDAE; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033141367     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.6.1081     Document Type: Article

References (25)

1. Harris CC: Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442-1455, 1996.
2. Jacks T and Weiberg RA: Cell-cycle control and its watchman. Nature 381: 643-644, 1996.
3. Kinzler KW and Vogelstein B: Cancer therapy meets p53. N Engl J Med 331: 49-50, 1994.
4. Nielsen LL and Maneval DC: p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 5: 52-63, 1998.
5. Fayrot M, Coll JL, Louis N and Negoescu A: Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy. Gene Ther 5: 728-739, 1998.
6. Xu L, Pirollo KF and Chang EH: Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum Gene Ther 8: 467-475, 1997.
7. Strobel T, Swanson L, Korsmeyer S and Cannistra SA: Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells. Oncogene 14: 2753-2758, 1997.
8. Pestell KE, Medlow CJ, Titley JC, Kelland LR and Walton MI: Characterization of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer 77: 913-918, 1998.
9. Trepel M, Groscurth P, Malipiero U, Gulbins E, Dichgans J and Weller M: Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. J Neurooncol 39: 19-32, 1998.
10. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, Buffa R, Ferrero S, Piazza M, Blandamura S, Segalin A, Bonavina L and Peracchia A: p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 79: 425-432, 1997.
11. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, Swalsky PA, Gooding WE and Posner MC: p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 83: 7-18, 1998.
12. Miller AD and Rosman GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques 7: 980-990, 1989.
13. Baker SJ, Markowitz S, Fearon ER, Willson JKV and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915, 1990.
14. Gunji Y, Tagawa M, Matsubara H, Takenaga K, Shimada H, Kondo F, Suzuki T, Nakajima K, Aoki T, Asano T, Ochiai T, Isono K, Kageyama H, Nakamura Y and Sakiyama S: Murine colon carcinoma cells engineered to produce human interleukin-2 induce tumor-specific anti-tumor response. Int J Cancer 66: 135-139, 1996.
15. Janik P, Briand P and Hartmann NR: The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res 35: 3698-3704, 1975.
16. Passlick B, Izbicki J, Riethmüller G and Pantel K: p53 in non-small cell lung cancer. J Natl Cancer Inst 86: 801-802, 1994.
17. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR and Bevilacqua G: p53 alterations arc predicative of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75: 230-235, 1997.
18. Wu GS and El-Deiry WS: p53 and chemosensitivity. Nat Med 2: 255-256, 1996.
19. Wu GS and El-Deiry WS: Apoptotic death of tumor cells correlated with chemosensitivity, independent of p53 and bcl-2. Clin Cancer Res 2: 623-633, 1996.
20. Findley HW, Gu L, Yeager AM and Zhou M: Expression and regulation of Bcl-2, Bcl-xL, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89: 2986-2993, 1997.
21. Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997.
22. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, Taya Y, Gabrielli B, Chan D, Lees-Miller SP and Lavin MF: ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 20: 398-400, 1998.
23. ARF links the tumor suppressor p53 to Ras. Nature 395: 125-126, 1998.
24. Casson AG, Tammemagi M, Eskandarian S, Redston M, McLaughlin J and Ozcelik H: p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol 51: 71-79, 1998.
25. Blagosklonny MV and El-Deiry WS: Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 75: 933-940, 1998.